Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial | Zendy

Sunanda V. Kane | Zendy

Open Access

Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial

Author(s) -

Sunanda V. Kane

Publication year - 2008

Publication title -

patient preference and adherence

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.885

H-Index - 48

ISSN - 1177-889X

DOI - 10.2147/ppa.s3698

Subject(s) - medicine , dosing , ulcerative colitis , tolerability , randomized controlled trial , clinical endpoint , interquartile range , inflammatory bowel disease , mesalazine , adverse effect , maintenance therapy , gastroenterology , disease , chemotherapy

Multiple studies have demonstrated the efficacy of aminosalicylates in maintaining remission in ulcerative colitis (UC). A newer formulation of mesalamine can be administered once daily. We aimed to examine the efficacy and tolerability of pH-dependent mesalamine for long-term maintenance, and compare the rates of medication consumption between groups over a prolonged period.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research